Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fresenius SE KGaAXSWX:FRE 73 Days Sales Outstanding is 59.68 as of Mar. 2026, which is 13% below its 10-year median of 68.55. GuruFocus rates XSWX:FRE with a GF Score™ of 73/100 and a GF Value™ of CHF34.48. The stock has 5 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 63.17% on this metric.
The historical rank and industry rank for Fresenius SE KGaA's Days Sales Outstanding or its related term are showing as below:
XSWX:FRE'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31 Med: 68.55 Max: 120.41
Current: 59.95
During the past 13 years, Fresenius SE KGaA's highest Days Sales Outstanding was 120.41. The lowest was 56.31. And the median was 68.55.
XSWX:FRE's Days Sales Outstanding is ranked worse than 63.17% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 47.19
vs XSWX:FRE: 59.95
Fresenius SE KGaA's Days Sales Outstanding
increased
from Mar. 2025 (57.32) to Mar. 2026 (59.68).
Fresenius SE KGaA (XSWX:FRE) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Fresenius SE KGaA Days Sales Outstanding Related Terms
Fresenius SE KGaA Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Days Sales Outstanding Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Days Sales Outstanding falls into.
Fresenius SE KGaA Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a Days Sales Outstanding of 59.68 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fresenius SE KGaA and its competitors. This is 13% below median its historical median of 68.55. Over the past decade, Fresenius SE KGaA's Days Sales Outstanding has ranged from 56.31 to 120.41. According to the industry distribution chart, Fresenius SE KGaA ranks #415 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 63.2%.
Is Fresenius SE KGaA's Days Sales Outstanding too high?
Fresenius SE KGaA's current Days Sales Outstanding of 59.68 is 13% below median its 10-year median of 68.55. Over the past 10 years, this metric has ranged from a low of 56.31 to a high of 120.41. The Healthcare Providers & Services industry median Days Sales Outstanding is 47.19. Fresenius SE KGaA's value of 59.68 is 26.5% above this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #415 out of 657 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Days Sales Outstanding compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #415 out of 657 companies for Days Sales Outstanding. This places Fresenius SE KGaA in the lower half of its industry. The industry median Days Sales Outstanding is 47.19. Fresenius SE KGaA's value of 59.68 is 26.5% above this benchmark. Historically, Fresenius SE KGaA's own Days Sales Outstanding has ranged from 56.31 to 120.41 over the past decade. While the company's 10-year median is 68.55 vs. the industry median of 47.19, Fresenius SE KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 47.19, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current Days Sales Outstanding of 59.68 is 26.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 47.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Days Sales Outstanding is 59.68, which is 13% below median its own 10-year median of 68.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Fresenius SE KGaA (XSWX:FRE) has a current Days Sales Outstanding of 59.68. The stock's GF Value™ is CHF34.48, compared to a current price of CHF39.27 — trading 13.9% above its estimated fair value. The current Days Sales Outstanding is 59.68, which is 13% below median its 10-year median of 68.55 and 26.5% above the Healthcare Providers & Services industry median of 47.19. Fresenius SE KGaA's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Days Sales Outstanding is 59.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF39.27 is trading 13.9% above its estimated GF Value™ of CHF34.48.
Key valuation signals for XSWX:FRE:
Days Sales Outstanding: 59.68 (13% below median its 10-year median of 68.55)
GF Value™: CHF34.48 vs. price of CHF39.27 (13.9% above fair value)
Industry Position: 26.5% above the Healthcare Providers & Services median (#415 of 657)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
73GF Score
Get the complete analysis for XSWX:FRE
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
